Wei Cuiling, Sing Chor Wing, Wan Eric Yuk Fai, Cheung Ching Lung, Wong Ian Chi Kei, Lai Francisco Tsz Tsun
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong SAR, China.
Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Sha Tin, Hong Kong SAR, China.
NPJ Prim Care Respir Med. 2025 Mar 25;35(1):18. doi: 10.1038/s41533-025-00424-y.
An infection of SARS-CoV-1, the causative agent of Severe Acute Respiratory Syndrome (SARS), may be followed by long-term clinical sequala. We hypothesized a greater 20-year multimorbidity incidence in people hospitalized for SARS-CoV-1 infection than those for influenza during similar periods. We conducted a retrospective cohort study using a territory-wide public healthcare database in Hong Kong. All patients aged ≥15 hospitalized for SARS in 2003 or influenza in 2002 or 2004 with no more than one of 30 listed chronic disease were included. Demographics, clinical history, and medication use were adjusted for in the inverse-probability-of-treatment-weighted Poisson regression analyses. We identified 1255 hospitalizations for SARS-CoV-1 infection and 687 hospitalizations for influenza. Overall crude multimorbidity incident rates were 1.5 per 100 person-years among SARS patients and 5.6 among influenza patients. Adjusted multimorbidity incidence rate ratio (IRR) was estimated at 0.78 [95% confidence interval (CI), 0.70-0.86) for SARS patients compared with influenza patients. Analysis by follow-up period shows a potentially greater risk among SARS patients in the first year of follow-up (IRR 1.33, 95% CI 0.97-1.84), with the risk in influenza patients increasing in subsequent years. Subgroup analyses by age and sex showed consistent results with the main analysis that SARS-CoV-1 infection was not followed by a higher incidence of multimorbidity than influenza. Notable differences in the patterns of multimorbidity were identified between the two arms. To conclude, we found no evidence of a higher multimorbidity incidence after hospitalization for SARS than for influenza over the long-term.
严重急性呼吸综合征(SARS)的病原体SARS-CoV-1感染后可能会出现长期临床后遗症。我们推测,在相似时间段内,因SARS-CoV-1感染住院的患者20年多病发病率高于因流感住院的患者。我们利用香港全地区公共医疗数据库进行了一项回顾性队列研究。纳入了所有年龄≥15岁、2003年因SARS住院或2002年或2004年因流感住院且患有不超过30种所列慢性病之一的患者。在逆概率治疗加权泊松回归分析中对人口统计学、临床病史和用药情况进行了调整。我们确定了1255例SARS-CoV-1感染住院病例和687例流感住院病例。SARS患者的总体粗多病发病率为每100人年1.5例,流感患者为每100人年5.6例。与流感患者相比,SARS患者的调整后多病发病率比(IRR)估计为0.78[95%置信区间(CI),0.70-0.86]。按随访期分析显示,SARS患者在随访第一年的风险可能更大(IRR 1.33,95%CI 0.97-1.84),而流感患者的风险在随后几年增加。按年龄和性别进行的亚组分析显示,结果与主要分析一致,即SARS-CoV-1感染后多病发病率并不高于流感。在两组之间发现了多病模式的显著差异。总之,我们没有发现证据表明SARS住院后长期多病发病率高于流感。